Body Composition Changes in Patients on GLP-1 Receptor Agonists Undergoing an Intensive Cardiac Rehabilitation Program.
BACKGROUND
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used for type 2 diabetes and obesity and produce significant weight loss. However, concerns have emerged about potential loss of skeletal muscle mass (SMM) with pharmacologic weight reduction, particularly in older adults...
